Abstract Library

#4461 Systemic anti-cancer therapy in gastroenteropancreatic neuroendocrine carcinoma (GEP-NEC): Insights from National Cancer Registration and Analysis Service (NCRAS)

Introduction: ENETS advocates the use of platinum-based chemotherapy in combination with Etoposide as first-line chemotherapy in advanced GEP-NEC. Available retrospective evidence is from small studies.

Conference:

Presenting Author: Mortagy M

Authors: Mortagy M, El Asmar M, Paisey S, White B, Chandrakumaran K,

Keywords: Systemic anti-cancer therapy, Chemotherapy, GEP-NEC, NCRAS,

#4357 Proof of concept and design of an externally controlled trial for patients with gastroenteropancreatic neuroendocrine carcinomas based on the randomised phase II BEVANEC trial

Introduction: Neuroendocrine carcinomas of digestive or unknown primary trials are challenging to perform because of disease rarity. BEVANEC trial randomised 126 patients to FOLFIRI +/- bevacizumab in second line, over 5 years, and reported similar overall survival (OS) in both arms.

Conference:

Presenting Author: Hadoux J

Authors: Ganame S, Walter T, Durand A, Lièvre A, Tougeron D,

Keywords: Neuroendocrine carcinoma, synthetic control arm, external control arm, new clinical trial design, randomisation algorithm, real-world data, invers probability weighting,

#4018 Exploring the expression of DLL3 in gastroenteropancreatic neuroendocrine carcinomas and its potential diagnostic value

Introduction: The targeted treatment of DLL3 has attracted attention because of improving the prognosis of small cell lung cancer (SCLC), but the related research on DLL3 in GEP-NEC is relatively rare.

Conference:

Presenting Author:

Authors: Yin L, Jiang K, Zhao X, Hu Y, Lu M,

Keywords: DLL3, gastroenteropancreatic neuroendocrine carcinoma, targeted therapy, diagonsis,

#3704 Impact of surgical approach on short- and long-term outcomes in gastroenteropancreatic neuroendocrine carcinomas

Introduction: Complete resection is the cornerstone of curative-intent treatment for gastroenteropancreatic neuroendocrine carcinomas (GEP-NECs) without distant metastases. However, there is a paucity of data on the impact of recent advancements in minimally invasive surgery (MIS), such as the utilization of laparoscopic and robotic approaches, on GEP-NEC patients’ outcomes.

Conference:

Presenting Author: Chen Q

Authors: Chen Q, Rhodin K, Li K, Kanu E, Zani S,

Keywords: Gastroenteropancreatic neuroendocrine carcinoma, Minimally Invasive Surgery, Open resection, Laparoscopic resection, Robotic resection, Outcome,

#3657 Prognostic and therapeutic role of a novel genomic subtyping of target gene sequencing on gastroenteropancreatic neuroendocrine carcinoma

Introduction: Despite of emerging genomic discoveries, no optimal management for gastroenteropancreatic neuroendocrine carcinoma (GEPNEC) were found.

Conference:

Presenting Author:

Authors: Zhang J, Li J, Lu M, Sun Y, Shen L,

Keywords: Gastroenteropancreatic Neuroendocrine carcinoma, Target gene sequencing, Genomic subtyping, Efficacy, Prognosis, Second-line treatment,